Industry – Page 30 – Swanson Reed | Specialist R&D Tax Advisors

Tethon 3D Patents Genesis Printing Resins

New Mexico Patent of the Month - June 2021

Nebraska-based Tethon 3D has officially patented their genesis 3D printing resins. Tethon 3D is focused on revolutionizing ceramic 3D printing by developing novel and innovative resins. They develop and manufacture ceramic powders and photo curable ceramic, metal and polymer resins, each of which can be used in 3D printing.

Their new patent, titled “Photopolymer Development Resin Base for Use with Three-Dimensional Printer” covers the entirety of their Genesis product line – a series of base resins. These products aren’t suitable for 3D printing on their own, they serve as a development base and can be mixed with solid powdered additives to formulate polymer-based composites. These composites can then be 3D printed on SLA and DLP systems. Genesis acts as a starting point for photopolymer resin research and development when adding in solid powders with potential applications in a wide range of industries from dentistry to jewelry to biotech.

Right now Tethon 3D is advertising Tethon 3D as designed for experimental use with a set of guidelines. They also encourage experimentation outside of the guidelines. Tethon 3D formulated this product with specific goals in mind, working towards high loading and physical flexibility. These goals allow for a border range of solid materials to be added into the Genesis line.

Since the launch of Genesis in 2016, numerous customers have experimented with the base resin. Using this base allows customers to add their own custom ingredients to formulate novel ceramics without needing to worry about the lower-level materials science details. This could speed up and enhance resin development across the board.

Tethon 3D has been plenty busy recently, having just announced a partnership with Mechnano, an additive manufacturing materials company. This partnership will work to develop a novel high-temperatures, ESD-safe resin for 3D printing. Called C-lite, this material will withstand temperatures of up to 225°C and uses Mechnano’s proprietary carbon nanotube technology to dissipate static.

Are you developing new products for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Unconventional Gas Solutions Launches Verdant Process Systems

Unconventional Gas Solutions, LLC (UGS) is committed to the development of specialized membranes for gas generation and processing. They have recently launched a new line of process solutions for renewable natural gas (RNG), renewable hydrogen production, and hydrogen recovery from industrial processes. This line is coined Verdant Process Systems ™ and leverages the gas separations expertise of the UGS team.

UGS has an extensive history and expertise in process design and packaging, which Verdant Process Systems can base their system on. Their approach is based on technology selection and process design to optimize cost and carbon intensity with the ultimate goal of providing industry-leading methane emissions control across the system.

Verdant Process Systems will have a rapid start, taking on 8 new projects for the “flange-to-flange” turnkey biogas upgrading systems for the production of RNG. UGS was selected for these projects and intends to give Verdant Process Systems the support needed to get some of these projects online over the next 2 years.

UGS also announces a contract to purchase a 70,000 square foot Engineering, Fabrication & Assembly facility in Houston. The new, multi-building facility will house all of UGS’ fabrication and assembly activities. The facility will capture significant synergies with the supply chains available in the Houston area as well as the region’s growing renewable energy ecosystem. The new facility will complement the company’s Houston headquarters, the Business Development office in Wilmington, Delaware, and its R&D facility in Boston.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Ideal Aerosmith Awarded $17M Contract

The New Program Dedicated to Keeping Mississippi at the Forefront of Technology

The Office of Naval Research (ONR) has awarded North Dakota-based Ideal Aerosmith, Inc. a massive contract for the creation of an Expeditionary Mission Support Station (EMSS). This contract comes in at a maximum of $25,685,970 cost-plus-fixed-feed deal. And will include a ground station for controlling multiple unmanned aircraft and sensor systems.

The contract is funded at $17 million, but includes a 12-month option period which would bring the total up to $25 million. This optional period funding has not yet been approved.

Ideal Aerosmith is best known for their motion testing technology. They work to develop innovative motion testing solutions from hardware to software. This motion simulation testing can be applied to a variety of industries including aerospace, automotive electronics, and petroleum industries around the world.

The contract with EMSS will include updating the advanced mission planning systems and is strategically important for allowing dedicated Intelligence, Surveillance, and Reconnaissance (ISR) assets and the collection of this ISR data for use in the planning process. Ideal Aerosmith will create the mission planning software capable of collecting and processing this ISR data – both classified and non-classified. They will aim to make the software capable of planning multi-day routes with dynamic weather considerations which may change over both time and location.

“The technology developed under this contract will help missions across the globe to be better informed, supporting the safety and effectiveness of our servicemembers,” said Senator John Hoeven. Hoeven had been working with the ONR to secure this deal with Ideal Aerosmith.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Pluton Furthers Understanding of Bacteria Capable of Killing Mosquitoes

Louisiana Patent of the Month - August 2021

Pluton Biosciences has recently announced their participation in the Wells Fargo Innovation Incubator (IN2) program has generated a deeper understanding of how three novel bacteria work to kill disease-carrying mosquitoes. One of these is a larvicidal bacteria capable of killing the disease-carrying Aedes aegypti mosquito.

This Missouri-based company was founded in 2017 and is composed of a team of talented scientists, entrepreneurs, and technologists. They explore the diverse world of microorganisms in an effort to develop clean, eco-friendly products for carbon sequestration, agriculture, pharmaceuticals, biomaterials, and bioremediation. They developed a proprietary platform called the Micromining ® Innovation Engine which helps their scientists discover microbes with novel activities in only a few months.

During their time in IN2’s seventh cohort, they performed R&D activities at the Donald Danforth Plant Science Center in St. Louis. With Danforth’s biochemistry expertise, Pluton’s researchers have unraveled the chemistry behind three novel bioinsecticides discovered back in 2017. Previous developments by Pluton include microbes that have the potential to save crops, kill pests, reduce diseases, and even break down plastic waste.

In addition to working in the IN2 cohort, Pluton received $250,000 in technical assistance to further research into these three novel bacteria. This also came with access to state-of-the-art expertise and resources in the Danforth Center. Between funding and technology, pluton has doubled down on their research and intends to continue working with these novel bacteria characteristics.

Are you developing new biotechnology for a new application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Sartorius AG to Open Center of Excellence in Michigan

Sartorius AG, a German laboratory and pharmaceutical equipment provider, announced their plans to expand into Michigan. This move will include the opening of a new 130,000 sqft. State-of-the-art plant in Ann Arbor in late 2023.

Theis Ann Arbor location will consolidate existing operations in Washtenaw County, creating a Center of Excellence for both the Laboratory and Bioprocess Products and Services in North America. This center of excellence will create 160 jobs from operations to product development. Product development will include the development of innovative solutions to help customers create drugs that cure, prevent, or halt the progression of diseases.

Sartorius produces their biopharmaceuticals using living cells. Their innovative methods simplify workflows and minimize human errors. Sartorius has been pioneering and setting the standards for single-use products used throughout all biopharmaceutical manufacturing processes. By expanding into Michigan and creating a center of excellence, they can help to expand innovation in the industry while contributing to the state’s economy.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Eco Depot Acquires Remaining Shares of Development One

Eco Depot Inc. has announced their acquisition of Development One Nanotechnologies and Energy Inc.

Development One is a Wyoming-based corporation specializing in the R&D of nano carbon atoms and polymer products within the coatings and construction industries. Eco Depot Inc has acquired all outstanding common shares of Development One.

Development One has previously developed a proven coating for the industrial space capable of increasing strength by 300% while lowering friction. It is also less abrasive and lubricating than other options. They have also developed other products like cement additives which can improve tool life and efficiency in the oil and gas industry.

Eco Depot acquires, manages, and develops eco-friendly real estate assets and consumer and industrial brand products. Development One works with industry leaders to address infrastructure issues related to corrosion. Between their R&D skills and Eco Depot’s focus on investing in green technologies, the two companies will continue to advance the future of concrete while reducing the carbon footprint of the industry.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Second Genome Collaborates with VCU to Develop Diagnostic Biomarker for NASH

Second Genome is a tech-enabled biotech company that extracts microbial genetic insights to guide their transformational precision therapies and biomarkers. They find these insights using their proprietary platform – sg-4sight. Recently, they have announced a research collaboration with Virginia Commonwealth University (VCU) as they work to generate a non-invasive stool-based composite biomarker for non-alcoholic steatohepatitis (NASH).

Second Genome will use their sg-4sight discovery engine’s machine learning capabilities to identify composite biomarkers that can diagnose patients with NASH who have advanced fibrosis. This will require the characterization of the GI microbial taxa and microbial transcriptome in NASH. They will also characterize these taza in non-alcoholic fatty liver disease (NAFLD) patients. VCU’s Dr. Arun Sanyal, a professor of Medicine, Physiology, and Molecular Pathology, will provide geographically diverse patient samples, clinical meta-data, liver biopsy images and a biorepository. Once Second Genome identifies the biomarker, the model will be clinically validated in patients enrolled in the VCU biorepository.

The present gold standard diagnosis for patients living with NASH is a highly invasive liver biopsy with critical side effects. Dr. Sanyal says there is a significant need to advance non-invasive diagnostic approaches and believes Second Genome’s machine learning capabilities and microbial expertise will be key to developing a non-invasive diagnostic marker.

Are you developing new biotechnology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

SAB Biotherapeutics COVID-19 Candidate to Advance to Phase 3 Trials

SAB Biotherapeutics (SAB) is focused on revolutionizing immunotherapies. They operate as a clinical-stage biopharmaceutical company, utilizing their proprietary immunotherapy platform to produce specifically targeted, high-potency, fully-human polyclonal antibodies. Part of the revolutionary aspect of this technology is that it does not require human donors at all. Recently, SAB received positive news from an independent Data Safety Monitoring Board (DSMB) regarding the safety and efficacy of SAB-185 – their current therapeutic candidate for patients with moderate COVID-19.

SAB-185 has been subjected to a prespecified interim analysis data review, evaluating the safety and efficacy in the Phase 2 portion of the ACTIV-2 trial. The DSMB has given full approval and recommended advancement to Phase 3, a major milestone for their platform.

SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for the treatment of non-hospitalized patients with moderate COVID-19. After meeting the predefined graduation criteria, this candidate will move to Phase 3 trials, showing it has true potential to become a valuable therapy. Following Phase 3, if successful, SAB will work on scaling up production to make their therapy as widely available as needed.

The Phase 3 portion of the ACTIV-2 trial is a randomized, unblinded, active comparator-controlled adaptive platform study that will assess the clinical safety and efficacy of SAB-185 compared to active control monoclonal antibody treatment in people with mild to moderate COVID-19 who are at higher risk for progression to hospitalization, enrolling approximately 600 participants to receive the investigational agent SAB-185 and 600 to receive an active comparator. The primary outcome measures of the Phase 3 trial will include safety and non-inferiority for the prevention of a composite endpoint of either hospitalization or death from any cause through study day 28.

Are you developing new pharmaceuticals? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Velocity Clinical Research Brings VitaLink and NRI Sites into their Realm

Virginia Patent of the Month - August 2021

Velocity Clinical Research has announced they will officially acquire two multi-site companies – VitaLink Research and National Research Institute (NRI) for an undisclosed amount. They believe this acquisition will enhance Velocity’s therapeutic reach and recruiting power.

VitaLink, a South Carolina-based research company – has a network of 6 sites in the state. California-based NRI has 5 sites throughout the greater Los Angeles area. This dual acquisition adds a total of 11 new sites to Velocity’s existing 18, making it the largest fully integrated site management organization in the world.

They intend to integrate management from both companies, filling key roles in Velocity and strengthening its senior management bench. North Carolina-based Velocity is the leading integrated site organization for clinical trials. This unique position allows them to help biopharmaceutical and contract research organization customers find the right patients for their studies. This integrated approach benefits both sponsors and study participants.

As they expand their reach and site availability, Velocity is on track to advance the clinical trial field and speed up the testing and trialing of experimental pharmaceuticals. Each acquisition is based on careful vetting of the research site. They look for dedicated research clinics with experienced physician investigators and research staff. They are also interested in achieving a sufficient geographical dispersion across the country to ensure their access reaches minority populations and provides sufficient patient diversity.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

JSR to Acquire Oregon Start-Up, Inpria, for $514M

ETRAK Technologies to Compete for $75K in Funding from Alabama Launchpad

Inpria Corp., a start up with origins in Oregon State University, has developed revolutionary materials used in microchips. Recently, they have announced they will be acquired by the Japanese firm JSR for $514 million.

This revolutionary material comes in the form of a first-of-its-kind inorganic photoreactive liquid which can improve the production of more powerful, cost-effective, and energy-efficient microchips used in all sorts of electronics. This inorganic, tin-oxide base is put through a photolithography process to produce the semiconductor microchips. This process involves applying a nanometer-thin layer of their light-sensitive solution to a silicon wafer, using extreme UV (EUV) light to record and replicate a stencil pattern onto the chemical coated wafer. This can then be transferred to create the circuit patterns. The short wavelengths of EUV allow for the smallest possible patterning.

The more precise the patterning materials and process, the smaller patterns manufacturers can create, which allows for production of more powerful and energy-efficient semiconductor microchips.

After their founding in 2007, Inpria drew plenty of attention and attracted investors like Intel and Samsung. These big players also believe that Inpria’s technology could be the next step in progressing the development of chips and processors.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.